BRAF and neoplasm: For clarity, we define “regressing tumors” as those undergoing active shrinkage during the early phase of BRAF/MEKi treatment (e.g., day 3), while “residual disease” refers to the stabilized, therapy‐tolerant tumor state observed after prolonged treatment (e.g., day 14), prior to overt resistance.